United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market. byPallavi MadhirajuSeptember 10, 2025